Seeking Alpha

New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy

SUBLOCADE use during pregnancy showed no increased risk of birth defects, miscarriage, or maternal complications compared to general population rates RICHMOND, Va., May 1, 2025 /PRNewswire/ -- ...
Seeking Alpha

Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment

RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two approaches ...

New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization

Compared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent and non-adherent) were 3.5 to 8.1x more ...
Monthly Prescribing Reference

Updated Sublocade Label Includes Rapid Induction, Alternative Injection Sites

Patients not already receiving buprenorphine can receive the first injection of Sublocade following a single dose of transmucosal buprenorphine and a 1 hour observation period to confirm tolerability.
Morningstar

Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment

The study found that rapid induction—administration of a single dose of 4-mg oral buprenorphine followed by a same-day SUBLOCADE injection—was well tolerated and led to higher retention at the second ...